Mitchel Sayare replaces John Pappajohn as PharmAthene's chairman
This article was originally published in Scrip
PharmAthene, a biodefence company developing medical countermeasures against biological and chemical threats, has elected Dr Mitchel Sayare chairman of the board, succeeding John Pappajohn who has stepped down from the board. Dr Sayare has been a PharmAthene board member since April 2010, and previously served from 1985 to 2010 as chairman and CEO of ImmunoGen.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.